New Capital Strengthens ProtaGene's Advanced Analytical Leadership in the Biologics and Cell and Gene Therapy Markets
ProtaGene, a leading global contract research organization (CRO) dedicated to advanced analytics for biologics and cell…
ProtaGene GmbH
Confronting Molecular Bioanalysis Challenges in Gene Therapy Development
As the gene therapy sector continues to mature, regulators’ expectations for more robust product understanding are growi…
Navigating CMC Challenges in NBE and Therapeutic Antibody Development
In April 2021, the FDA approved the 100th monoclonal antibody as a therapeutic entity, a milestone that took 35 years to…
ProtaGene Appoints New Scientific and Commercial Leadership to Support Evolving Needs of Biologic and Cell & Gene Therapy Innovators
ProtaGene GmbH, a leading global contract research organization focused on advanced analytics in biologics and cell and…
Foundation for the Industry's Next-stage Innovation and Growth
ProtaGene is thrilled to announce the planned opening of our brand-new, state-of-the-art lab and office headquarters in…
Analytical Service Leaders in Biopharmaceutical and Gene Therapy Development Unify Operations and Re-brand as ProtaGene
Following the announced merger in July 2021, Protagen Protein Services GmbH, BioAnalytix, Inc., and GeneWerk GmbH today…
Protagen Protein Services Merges with GeneWerk to Integrate Leading Protein and Gene Therapy Analytic Platforms
Protagen Protein Services (PPS) today announced that it will merge with GeneWerk, an Ampersand portfolio company. With t…
